Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance

‘Our Focus Is On Driving Long-Term EBITDA Growth,’ Endo Insists

 
• By Dean Rudge
  
Expanding portfolio is Endo's first priority • Source: OleksandrShnuryk/Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business